Navigation Links
AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
Date:5/18/2009

WILMINGTON, Del., May 18 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that all wholesale ordering restrictions in place for TOPROL-XL(R) (metoprolol succinate) extended release tablets have been removed and that supply levels of TOPROL-XL are approaching near usual levels at all points in the distribution chain.

AstraZeneca has been diligently working to help ensure adequate market supply of TOPROL-XL and the authorized generic metoprolol succinate following published reports that two generic companies had recalled or suspended shipments of metoprolol succinate in late 2008 and early 2009.

"After the two generic manufacturers stopped supplying the market, it was critical that we quickly boost our production to increase the supply available for patients," said Kathy Monday, Vice President at AstraZeneca.

To help ensure equitable distribution of TOPROL-XL, AstraZeneca had initially instituted a short-term order management system to wholesalers. That system has now been lifted as AstraZeneca is now manufacturing and distributing enough TOPROL-XL and authorized generic metoprolol succinate to meet historical demand levels. The authorized generic is distributed and marketed by Par Pharmaceutical.

"TOPROL-XL and metoprolol succinate should now be available for patients in all regions across the country," said Monday.

AstraZeneca has been manufacturing TOPROL-XL for the US market since 1992 and is making significant investments in order to help ensure that supply is available to meet the needs of patients in the US, while not impacting supply available to patients in the rest of the world.

TOPROL-XL and metoprolol succinate patients should always consult with their health care professional if they have concerns about their medication. Patients should never disrupt or change their TOPROL-XL or metoprolol succinate dosing without consulting their health care professional first.

Important Safety Information About TOPROL-XL(R) (metoprolol succinate) Extended-Release Tablets

TOPROL-XL is a beta(1)-selective (cardioselective) adrenoceptor-blocking agent, for oral administration, available as extended-release tablets. TOPROL-XL has been formulated to provide a controlled and predictable release of metoprolol for once-daily administration.

TOPROL-XL is indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long-term treatment of angina pectoris; and the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in heart failure patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis.

TOPROL-XL is contraindicated in severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, and sick sinus syndrome (unless a permanent pacemaker is in place) and in patients who are hypersensative to any component of this product.

Patients taking TOPROL-XL should avoid abrupt cessation of therapy. Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infraction have occurred. The dosage should be reduced gradually over a one-to-two-week period, and the patient should be carefully monitored.

TOPROL-XL should be used with caution in patients who have bronchospastic disease, diabetes, thyrotoxicosis, peripheral vascular disease, who are undergoing major surgery, or who take calcium channel blockers of the verapamil and diltiazem type.

There is a risk of worsening cardiac failure during up-titration of the dose of TOPROL-XL. Patients need to consult their physicians if they experience signs or symptoms of worsening heart failure such as weight gain or increased shortness of breath.

Patients should be advised to (1) avoid operating automobiles and machinery or engaging in other tasks requiring alertness until the patient's response to therapy with TOPROL-XL(R) (metoprolol succinate) has been determined; (2) contact a physician if any difficulty in breathing occurs; (3) inform the physician or dentist before any surgery that he or she is taking TOPROL-XL.

In clinical trials of patients with hypertension and angina pectoris the most common adverse events reported with immediate-release metoprolol tartate are tiredness (10%), dizziness (10%), depression (5%), diarrhea (5%) pruritus or rash (5%), shortness of breath (3%) and bradycardia (3%).

In patients with heart failure, serious adverse events and adverse events leading to discontinuation of study medication in MERIT-HF at an incidence greater than or equal to 1% in the group receiving TOPROL-XL and greater than placebo by more than 0.5% were dizziness/vertigo (1.8% vs 1.0%), bradycardia (1.5% vs 0.4%) and accident and/or injury (1.4% vs 0.8%).

For full Prescribing Information for TOPROL-XL including boxed WARNING regarding abrupt cessation of therapy, call 1-800-236-9933 or visit www.astrazeneca-us.com

About AstraZeneca

AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services.

AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business.

For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com.


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ingenuity Systems Announces Multi-Year Deal With AstraZeneca
2. Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation
3. FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site
4. AstraZenecas David Brennan Elected PhRMA Board Chairman
5. Video: Astrazeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
6. AstraZeneca Applauds Appointment of New FDA Commissioner
7. AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
8. Palatin Technologies Announces Receipt of $4.1 Million from AstraZeneca
9. AstraZeneca Helped More Than 440,000 Patients Save $612 Million on Medicines in 2008
10. AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
11. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... 12, 2017 , ... Planet Fitness, one of the largest and fastest growing ... open a flagship location in Covington, LA at 401 N. U.S. Highway 190, in ... to Office Depot in the Holiday Square shopping center. Its location allows it to ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  BioPharmX Corporation (NYSE MKT: BPMX) researchers were part ... way to use nonlinear optical imaging to confirm the ... A presentation ... how researchers from BioPharmX and the Wellman Center for ... suite of imaging techniques in what is called "Pharmacokinetic ...
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance ... a medical-grade battery-powered display stand specifically designed for endoscopy environments. An ... technology into a clinical solution to support the improvement of patient ... Innovative Design ... Wireless Solution ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: